logo
  Join        Login             Stock Quote

Insiders Are Spending Millions On These 4 Small-Cap Stocks

 April 10, 2012 11:23 PM
 


If you want someone to really pay attention to what you are saying, then all you have to do is put your money where your mouth is.

Consider the CEO of Company X. His stock price is in the proverbial toilet. He can't get a break on Wall Street, and the problems on Main Street aren't looking like they're going to do much for his bottom line, either.  No one is too surprised if he sells shares of his own company's stock.

But what if he starts buying? That's a whole other ball game, isn't it? The executive management and board members know what's really going on and how the company can react to it.

That's the point of monitoring insider transactions.

So today, we're going to look at potentially game-changing companies insiders have been buying.

Using the Bloomberg Professional Service, I performed a special search function to display all insider trades for the past six months with a market value of more than $1 million. Because stock is often part of an executive's total compensation package, I excluded filings that were made to exercise stock options.

Here are what I believe to be the most illuminating insider trades of true game-changing stocks from the past six months...

1. Amyris (Nasdaq: AMRS)
This is a biofuel company, but that's not the whole story -- not by a long shot. The better description for Amyris is as a "synthetic biology" company. Its scientists use special organisms that are basically little living factories that have been genetically programmed to produce a certain compound. This process leverages the natural abilities of plants to process sugar, and renewable sources of plant sugar is the inevitable future of fuel.

Amyris is a pioneer in this field. The company was founded in 2003 and won grant funding from the Bill & Melinda Gates Foundation to develop the underpinning of an anti-malaria drug. The effort was a complete success, and Amyris licensed the technology to drug giant Sanofi (NYSE: SNY), the largest vaccine maker in the world.

Now the company is setting its sights on biofuel, specifically on generating cellulosic ethanol from Brazilian sugarcane.

What would be perfect here is for me to tell you that this buy was made by a notable energy expert with unassailable credentials.

Next Page >>123
iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageLadenburg Thalmann Financial Services (NYSEMKT:LTS): Heavy, Durable Insider Buying

Ahh, but any worries over price levels didn’t stop multiple insiders at Ladenburg Thalmann Financial read on...

article imageInternational Business Machines Corp. (IBM) Q2 Earnings Preview: Small Beat and Pop

International Business Machines Corp. (NYSE:IBM) will host a conference call Wednesday, Jul. 16, 2014 at read on...

article imageGoogle Inc. (GOOGL) Q2 Earnings Preview: A Few Pennies Either Way Make a Big Difference.

Google Inc. (NASDAQ:GOOGL) will hold its quarterly conference call to discuss second quarter 2014 financial read on...

article image19 Companies That Could Beat Earnings and Pop on Price Next Week

Using iStock’s proprietary iEstimates model, we have identified 19 publicly traded companies that could read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.